Результати пошуку - Joanna Schmidt

  • Показ 1 - 5 результатів із 5
Уточнити результати
  1. 1
    HER Kinase Axis Receptor Dimer Partner Switching Occurs in Response to EGFR Tyrosine Kinase Inhibition despite Failure to Block Cellular Proliferation

    HER Kinase Axis Receptor Dimer Partner Switching Occurs in Response to EGFR Tyrosine Kinase Inhibition despite Failure to Block Cellular Proliferation за авторством Anjali Jain, Elicia Penuel, Sheldon Mink, Joanna Schmidt, Amanda Hodge, Kristin Favero, Charles Tindell, David B. Agus

    Опубліковано 2010
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  2. 2
    Enhanced Potency of GalNAc-Conjugated Antisense Oligonucleotides in Hepatocellular Cancer Models

    Enhanced Potency of GalNAc-Conjugated Antisense Oligonucleotides in Hepatocellular Cancer Models за авторством Youngsoo Kim, Minji Jo, Joanna Schmidt, Xiaolin Luo, Thazha P. Prakash, Tianyuan Zhou, Stéphanie Klein, Xiaokun Xiao, Noah Post, Zhengfeng Yin, A. Robert MacLeod

    Опубліковано 2019
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  3. 3
    Sphingosine Kinase Activity Is Not Required for Tumor Cell Viability

    Sphingosine Kinase Activity Is Not Required for Tumor Cell Viability за авторством Karen Rex, Shawn Jeffries, Matthew L. Brown, Timothy J. Carlson, Angela Coxon, Flordeliza Fajardo, Brendon Frank, Darin J. Gustin, Alexander Kamb, Paul D. Kassner, Shyun Li, Yihong Li, Kurt Morgenstern, Matthew Plant, Kim Quon, Astrid Ruefli-Brasse, Joanna Schmidt, Elissa Swearingen, Nigel P.C. Walker, Zhong Lin Wang, J. E. Vivienne Watson, Dineli Wickramasinghe, Mariwil G. Wong, Guifen Xu, Holger Wesche

    Опубліковано 2013
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  4. 4
    AZD9150, a next-generation antisense oligonucleotide inhibitor of <i>STAT3</i> with early evidence of clinical activity in lymphoma and lung cancer

    AZD9150, a next-generation antisense oligonucleotide inhibitor of <i>STAT3</i> with early evidence of clinical activity in lymphoma and lung cancer за авторством David S. Hong, Razelle Kurzrock, Youngsoo Kim, Richard Woessner, Anas Younes, John Nemunaitis, Nathan Fowler, Tianyuan Zhou, Joanna Schmidt, Minji Jo, Samantha J. Lee, Mason Yamashita, Steven G. Hughes, Luis Fayad, Sarina A. Piha‐Paul, Murali V.P. Nadella, Morvarid Mohseni, Deborah Lawson, Corinne Reimer, David C. Blakey, Xiaokun Xiao, Jeff Hsu, Alexey S. Revenko, Brett P. Monia, A. Robert MacLeod

    Опубліковано 2015
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  5. 5
    STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial

    STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial за авторством Matthew J. Reilley, Patricia McCoon, Carl Cook, Paul D. Lyne, Razelle Kurzrock, Youngsoo Kim, Richard Woessner, Anas Younes, John Nemunaitis, Nathan Fowler, Michael A. Curran, Qinying Liu, Tianyuan Zhou, Joanna Schmidt, Minji Jo, Samantha J. Lee, Mason Yamashita, Steven G. Hughes, Luis Fayad, Sarina A. Piha‐Paul, Murali V.P. Nadella, Xiaokun Xiao, Jeff Hsu, Alexey S. Revenko, Brett P. Monia, A. Robert MacLeod, David S. Hong

    Опубліковано 2018
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:

Інструменти для пошуку: